Metabolic disease
Therapeutic area
Metabolic Disease
Rare disease
No
- Definition
- A congenital disorder (due to inherited enzyme abnormality) or acquired (due to failure of a metabolically important organ) disorder resulting from an abnormal metabolic process.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Metabolic disease
- Therapeutic area
- Metabolic Disease
- metabolic disease
- disorder of metabolic process
- metabolic disorder
- Metabolic Disorder, Glucose
- Metabolic Disorders
- metabolic process disease
- Nutritional and Metabolic Disease
- All therapeutic areas
- Metabolic Disease
Sources for recorded values
- Severity
- Unknown
- MONDO ID
- MONDO:0005066
- Parent condition
- MONDO:7770007
Related records
Broader conditions (3)
- Disease
- Disease by developmental or physiological process
- Human disease
Narrower conditions (2,217)
- 2-aminoadipic 2-oxoadipic aciduria
- 2-hydroxyglutaric aciduria
- 2-methylacetoacetyl CoA thiolase deficiency
- 2-methylbutyryl-CoA dehydrogenase deficiency
- 3-hydroxy-3-methylglutaric aciduria
- 3-hydroxy-3-methylglutaryl-CoA synthase deficiency
- 3-hydroxyacyl-CoA dehydrogenase deficiency
- 3-hydroxyisobutyric aciduria
- 3-hydroxyisobutyryl-CoA hydrolase deficiency
- 3-methylcrotonyl-CoA carboxylase 1 deficiency
- 3-methylcrotonyl-CoA carboxylase 2 deficiency
- 3-methylcrotonyl-CoA carboxylase deficiency
- 3-methylglutaconic aciduria
- 3-methylglutaconic aciduria type 1
- 3-methylglutaconic aciduria type 3
- 3-methylglutaconic aciduria type 4
- 3-methylglutaconic aciduria type 5
- 3-methylglutaconic aciduria type 8
- 3-methylglutaconic aciduria type 9
- 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome
Trials (1,253)
- "Beverage Hydration Index" of Commercial Therapeutic Beverages
- "SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia
- 0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill Children
- 0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Hospitalized Children
- 4D-310 in Adults With Fabry Disease and Cardiac Involvement
- A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
- A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)
- A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
- A Clinical Study to Map the HLA Genomic Region in the Greek Population
- A Clinical Trial to Assess the Efficacy and Tolerance of a Berberine-based Nutraceutical Formula to Aid Blood Sugar Regulation and Metabolism
- A Clinical Trial to Evaluate the Effects of an Electrolyte Supplement on Women's Wellness
- A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg
- A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters
- A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria
- A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
- A Feasibility Trial of a Bhangra Folk Dance Intervention to Improve Metabolic Health in Older Indian Women in the UK
- A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
- A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
- A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
Approved drugs (6)
- Alendronate sodium
- Dapagliflozin
- Eliglustat tartrate
- Saxagliptin
- Taliglucerase alfa
- Velaglucerase alfa
Drugs in development (34)
- Acarbose Phase 3
- Afegostat tartrate Phase 2
- Allopurinol Phase 1
- Antilymphocyte immunoglobulin (horse) Phase 2
- Apocynin Phase 1
- Bumetanide Phase 1
- Busulfan Phase 1
- Dextrose Phase 2
- Empagliflozin Phase 2
- Evinacumab Phase 1
- Fenofibrate Phase 3
- Fludarabine Phase 1
- Hydrogen Phase 1
- KD3010 Phase 1
- Kisspeptin Phase 1
- Kisspeptin-10 Phase 1
- Lovastatin Phase 1
- Melatonin Phase 1
- Metformin Phase 3
- Omega-3-acid ethyl esters Phase 3